ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The concurrent targeting of autophagy and BCR-ABL inhibition has surfaced as a viable approach to address the limitations associated with tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML).